Fujita, Kohei
Saito, Zentaro
Ito, Takanori
Imakita, Takuma
Oi, Issei
Kanai, Osamu
Yamamoto, Yuki
Hata, Hiroaki
Sawai, Satoru
Tanizawa, Kiminobu
Article History
Received: 21 February 2024
Accepted: 30 April 2024
First Online: 6 May 2024
Declarations
:
: This clinical trial was approved by the National Hospital Organization Kyoto Medical Center institutional review board (approval number: 23–051). The study is registered in the UMIN-Clinical Trials Registry as a retrospective study. The registration number is UMIN000053688. The study is a retrospective nature and no consent forms were obtained from patients. Instead, an opt-out method is used, which guarantees the right of research subjects to refuse to participate in the study. The Ethics Committee of the NHO Kyoto Medical Centre has approved these methods.
: Not applicable.
: Kohei Fujita has received research funds under contracts from MSD, AstraZeneca, and AN2 Therapeutics outside of the submitted work. Osamu Kanai has received research funds under contract from AstraZeneca outside the submitting work. Yuki Yamamoto is a board member and a stockholder of HiLung, Inc. All the other authors have no conflicts of interest to declare.